EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer

Mi Rim Lee, Sang Myung Woo, Min Kyeong Kim, Sung-Sik Han, Sang-Jae Park, Woo Jin Lee, Dong-Eun Lee, Sun Il Choi, Wonyoung Choi, Kyong-Ah Yoon, Jung Won Chun, Yun-Hee Kim iD und 1 weitere

Cancer Science · 2024-04 · 115 (4) · 1283-1295

DOI: 10.1111/cas.16104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 13.02.2024. Verfasst von Mi Rim Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea, National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutations in circulating tumor deoxyribonucleic acid (ctDNA) have been reported as representative noninvasive prognostic markers for pancreatic ductal adenocarcinoma (PDAC). Here, we aimed to evaluate single KRAS mutations as prognostic and predictive biomarkers, with an emphasis on potential therapeutic approaches to PDAC. A total of 128 patients were analyzed for multiple or single KRAS mutations (G12A, G12C, G12D, G12R, G12S, G12V, and G13D) in their tumors and plasma using droplet digital polymerase chain reaction (ddPCR). Overall, KRAS mutations were detected by multiplex ddPCR in 119 (93%) of tumor DNA and 68 (53.1%) of ctDNA, with a concordance rate of 80% between plasma ctDNA and tumor DNA in the metastatic stage, which was higher than the 44% in the resectable stage. Moreover, the prognostic prediction of both overall survival (OS) and progression‐free survival (PFS) was more relevant using plasma ctDNA than tumor DNA. Further, we evaluated the selective tumor‐suppressive efficacy of the KRAS G12C inhibitor sotorasib in a patient‐derived organoid (PDO) from a KRAS G12C‐mutated patient using a patient‐derived xenograft (PDX) model. Sotorasib showed selective inhibition in vitro and in vivo with altered tumor microenvironment, including fibroblasts and macrophages. Collectively, screening for KRAS single mutations in plasma ctDNA and the use of preclinical models of PDO and PDX with genetic mutations would impact precision medicine in the context of PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansProto-Oncogene Proteins p21(ras)Biomarkers, TumorDNA, NeoplasmMutationTumor Microenvironment

Stichwörter der Autor:innen

KRASKRAS G12C inhibitorcirculating tumor DNApancreatic ductal adenocarcinomapatient‐derived organoid

Substanzen

Proto-Oncogene Proteins p21(ras)Biomarkers, TumorDNA, NeoplasmKRAS protein, human

Autor:innen und Institutionen

  • Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.
  • Molecular Imaging Branch, Division of Convergence Technology, Research Institute of National Cancer Center, Goyang, Korea.
  • Center for Liver and Pancreatobiliary Cancer, Hospital, National Cancer Center, Goyang, Korea.
  • Immuno-Oncology Branch, Division of Rare and Refractory Center, Research Institute of National Cancer Center, Goyang, Korea.
  • Targeted Therapy Branch, Division of Rare and Refractory Center, Research Institute of National Cancer Center, Goyang, Korea.
  • Interventional Medicine Branch, Division of Clinical Research, Research Institute of National Cancer Center, Goyang, Korea.

ORCID-Profile: Yun-Hee Kim, Sun-Young Kong

Förderung

  • National Research Foundation of Korea
  • National Cancer Center

Zitieren

APA

Lee, M. R., Woo, S. M., Kim, M. K., Han, S. S., Park, S. J., Lee, W. J., Lee, D. E., Choi, S. I., Choi, W., Yoon, K. A., Chun, J. W., Kim, Y. H., & Kong, S. Y. (2024). Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Cancer Science, 115(4), 1283-1295. https://doi.org/10.1111/cas.16104

Vancouver

Lee MR, Woo SM, Kim MK, Han SS, Park SJ, Lee WJ, et al. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Cancer Science. 2024;115(4):1283-1295. doi:10.1111/cas.16104

BibTeX
@article{Lee2024,
  author = {Lee, Mi Rim and Woo, Sang Myung and Kim, Min Kyeong and Han, Sung-Sik and Park, Sang-Jae and Lee, Woo Jin and Lee, Dong-Eun and Choi, Sun Il and Choi, Wonyoung and Yoon, Kyong-Ah and Chun, Jung Won and Kim, Yun-Hee and Kong, Sun-Young},
  title = {Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {4},
  pages = {1283--1295},
  doi = {10.1111/cas.16104}
}
Kostenlos starten →